Pharmaceutical tablet
Latest Celgene Corporation Patents:
- TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON
- Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases
- Compounds and Compositions for Selective Degradation of Engineered Proteins
- Cereblon binding compounds, compositions thereof, and methods of treatment therewith
- Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
Portions of the tablet are shown in broken lines to indicate that those portions form no part of the claimed design.
Claims
The ornamental design for a pharmaceutical tablet, as shown and described.
D31133 | July 1899 | Lantz |
D301764 | June 20, 1989 | Contractor |
D302051 | July 4, 1989 | Contractor et al. |
5770225 | June 23, 1998 | Parekh et al. |
5824338 | October 20, 1998 | Jacobs et al. |
D403396 | December 29, 1998 | Lundbom et al. |
D408910 | April 27, 1999 | Lundbom |
D425614 | May 23, 2000 | Chen et al. |
D430285 | August 29, 2000 | Chen et al. |
D431076 | September 19, 2000 | Chen |
D434846 | December 5, 2000 | Chen |
6165513 | December 26, 2000 | Dansereau et al. |
D459798 | July 2, 2002 | Desesquelle |
D506544 | June 21, 2005 | Rinker et al. |
D515202 | February 14, 2006 | Chen |
D534646 | January 2, 2007 | Chang et al. |
D535021 | January 9, 2007 | Stawski et al. |
D564086 | March 11, 2008 | Nielsen et al. |
D671636 | November 27, 2012 | Nishino |
D735315 | July 28, 2015 | Bhat |
D741990 | October 27, 2015 | Ramos |
D787042 | May 16, 2017 | Parikh |
D787043 | May 16, 2017 | Parikh |
D10612561 | October 1999 | JP |
- U.S. Appl. No. 29/531,123, filed Jun. 23, 2015, Parikh et al.
- United States Patent and Trademark Office, Office Action issued in U.S. Appl. No. 29/524,022, dared Apr. 6, 2016.
- United States Patent and Trademark Office, Final Office Action issued in U.S. Appl. No. 29/524,022, dated Oct. 18, 2016.
- United States Patent and Trademark Office, Office Action issued in U.S. Appl. No. 29/524,022, dated Jan. 10, 2017.
- United States Patent and Trademark Office, Office Action issued in U.S. Appl. No. 29/525,253, dated Apr. 11, 2016.
- United States Patent and Trademark Office, Final Office Action issued in U.S. Appl. No. 29/525,253, dated Oct. 18, 2016.
- United States Patent and Trademark Office, Notice of Allowance issued in U.S. Appl. No. 29/525,253, dated Jan. 13, 2017.
- United States Patent and Trademark Office, Office Action issued in U.S. Appl. No. 29/531,113, dated Apr. 12, 2016.
- United States Patent and Trademark Office, Final Office Action issued in U.S. Appl. No. 29/531,113, dated Oct. 18, 2016.
- United States Patent and Trademark Office, Notice of Allowance issued in U.S. Appl. No. 29/531,113, dated Jan. 17, 2017.
- United States Patent and Trademark Office, Office Action issued in U.S. Appl. No. 29/531,123, dated Apr. 11, 2016.
- United States Patent and Trademark Office, Final Office Action issued in U.S. Appl. No. 29/531,123, dated Oct. 18, 2016.
Type: Grant
Filed: Jul 23, 2018
Date of Patent: Sep 3, 2019
Assignee: Celgene Corporation (Summit, NJ)
Inventors: Darshan Parikh (Bridgewater, NJ), Scott Burnside (Wilmington, NC), Sreenivas S. Bhat (Kendall Park, NJ), Jiping Liu (Basking Ridge, NJ)
Primary Examiner: Charles D Hanson
Application Number: 29/657,523